A series of novel nucleoside 5'-triphosphates and phosphoramidites containing alkyne or amino groups for the postsynthetic functionalization of nucleic acids were designed and synthesized. For this purpose, the new 3-aminopropoxypropynyl linker group was used. It contains two alternative functional capabilities: an amino group for the reaction of amino-alkynyl-modified oligonucleotides with corresponding activated esters and an alkyne group for the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. It was shown that a variety of methods of the attachment of the new linker can be used to synthesize a diversity of modified pyrimidine nucleosides.

Download full-text PDF

Source
http://dx.doi.org/10.1080/15257770.2011.595379DOI Listing

Publication Analysis

Top Keywords

novel nucleoside
8
nucleoside 5'-triphosphates
8
5'-triphosphates phosphoramidites
8
phosphoramidites alkyne
8
alkyne amino
8
amino groups
8
groups postsynthetic
8
postsynthetic functionalization
8
functionalization nucleic
8
nucleic acids
8

Similar Publications

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia.

Bioorg Chem

December 2024

Good Clinical Practice Development, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Electronic address:

Inhibition of human concentrative nucleoside transporter 2 (CNT2) could suppress increases in serum urate levels derived from dietary purines. However, the structural basis for substrate recognition of CNT2 is still unknown and only a few inhibitors have been reported. In this study, a homology model of CNT2 was constructed and residues T315, E316, N426, N491, E492, F536 and N538 were identified as binding sites for adenosine through site-directed mutagenesis and a H-adenosine uptake assay.

View Article and Find Full Text PDF

Wilms tumor 1-associated protein (WTAP) has been validated to be a crucial regulator in the tumorigenesis and advancement of diverse malignancies. This study intended to probe the impacts of WTAP on colorectal cancer (CRC) progression from the perspective of N6-methyladenosine (m6A) modification. The differential expression patterns of WTAP in clinical CRC samples and cultured cell lines were validated via qRT-PCR and western blot.

View Article and Find Full Text PDF
Article Synopsis
  • N6-methyladenosine (mA) modification is critical for managing ferroptosis-related RNAs, but its role in cholangiocarcinoma (CC) is still unclear.
  • Public databases revealed METTL16's overexpression in CC, indicating poor patient prognosis, and it was found to protect cells from ferroptosis by maintaining mitochondrial health and affecting iron and lipid metabolism.
  • Mechanistically, METTL16 enhances ATF4 mRNA stability through m6A modification, which helps prevent ferroptosis in CC, suggesting potential therapeutic targets in the condition.
View Article and Find Full Text PDF

Design, synthesis, and biological evaluation of novel 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs as anti-SARS-CoV-2 agents.

Antiviral Res

December 2024

State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, 510530, China; Guangzhou Henovcom Bioscience Inc, 11 Kaiyuan Rd, Guangzhou, Guangdong, China. Electronic address:

Article Synopsis
  • The COVID-19 pandemic, driven by the SARS-CoV-2 virus, poses ongoing health risks and highlights the need for new antiviral treatments due to the virus's ability to mutate.
  • Researchers designed and synthesized new 2'-deoxy-2'-spirooxetane-7-deazapurine nucleoside analogs to inhibit the replication of SARS-CoV-2.
  • Among these, nucleoside analog 11q showed the strongest antiviral effects, outperforming existing treatments like Remdesivir and indicating its potential as a future therapeutic option.
View Article and Find Full Text PDF

Background: The treatment management of human immunodeficiency virus (HIV)-2 infection presents greater challenges compared to HIV-1 infection, primarily because of inherent resistance against non-nucleoside reverse transcriptase inhibitors. Integrase strand transfer inhibitors, particularly dolutegravir, have improved treatment outcomes for people with HIV-2. Lenacapavir, a novel and potent antiretroviral capsid inhibitor, offers additional therapeutic options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!